Pharma — Maj 2023
-
Lundbeck får hævet kursmål af Deutsche Bank efter regnskab https://www.proinvestor.com/investornyt/984356/lundbeck-far-haevet-kursmal-af-deutsche-bank-efter-regnskab
-
Det har været en rigtig god uge for de pharma- og biotekaktier der debatteres flittigt her på Proinvestor. Tak for indsatsen og god weekend til alle.
-
Lundbeck: Bestyrelsesmedlem køber aktier for knap 2 mio. kr.
7:56
Jakob Riis, der er bestyrelsesmedlem i Lundbeck, har købt aktier i medicinalselskabet for knap 2 mio. kr.Det oplyser Lundbeck i en insidermeddelelse mandag morgen.
Bestyrelsesmedlemmet har købt 54.138 aktier for samlet 1.998.233,58 kr., svarende til en stykpris på 36,91 kr.
Købet er dateret til 12. maj.
Fredag blev B-aktien i Lundbeck handlet til 36,66 kr. efter et fald på 1,4 pct.
.\˙ MarketWire
-
Novozymes får løftet sit kursmål til 520 kr. fra 510 kr. af finanshuset Bernstein, der gentager den positive anbefaling "outperform".
-
hvad synes folk om lundbeck?
-
Biogen : Canada Accepts New Drug Submission For Lecanemab As Treatment For Early Alzheimer's Disease https://www.proinvestor.com/investornyt/986031/biogen-canada-accepts-new-drug-submission-for-lecanemab-as-treatment-for-early-alzheimers-disease
-
FDA Approves AbbVie's Rinvoq As Once-Daily Pill For Crohn's Disease In Adults https://www.proinvestor.com/investornyt/988250/fda-approves-abbvies-rinvoq-as-once-daily-pill-for-crohns-disease-in-adults
-
Months after joining, Teva CEO pulls curtain back on strategy to return to growth https://firstwordpharma.com/story/5741789
-
Lilly's peresolimab hits main goal in Phase II rheumatoid arthritis study https://www.proinvestor.com/boards/112684/
-
Sanofi:Dupixent Phase 3 COPD Results Presented At ATS & Published In New England Journal Of Medicine https://www.proinvestor.com/investornyt/989207/sanofidupixent-phase-3-copd-results-presented-at-ats-amp-published-in-new-england-journal-of-medicine
-
Sandoz : EMA Accepts MAA For Proposed Biosimilar Denosumab https://www.proinvestor.com/investornyt/991161/sandoz-ema-accepts-maa-for-proposed-biosimilar-denosumab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind